RecruitingEarly Phase 1NCT06438250
68Ga-JH04 PET/CT: Dosimetry and Biodistribution Studies
68Ga-JH04 PET/CT: Dosimetry and Biodistribution Study in Patients With Various Cancers
Sponsor
First Affiliated Hospital of Fujian Medical University
Enrollment
5 participants
Start Date
Mar 1, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
68Ga-JH04 is a novel radiotracer targeting fibroblast activation protein (FAP). In this study, we observed the safety, biodistribution, and radiation dosimetry of 68Ga-JH04 in patients with different types of cancer.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Various solid tumors with available histopathological findings
- Signed informed consent
Exclusion Criteria2
- pregnant or lactational women
- who suffered from severe hepatic and renal insufficiency
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUG68Ga-JH04
The dose will be 148-222 MBq given intravenously.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06438250
Related Trials
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
NCT0725273921 locations
A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)
NCT073023473 locations
NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma
NCT060126954 locations
Norris ORIEN Total Cancer Care
NCT029700451 location
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
NCT0638592519 locations